A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Open Access
- 1 January 2018
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 126 (1), 54-63
- https://doi.org/10.1002/cncy.21928
Abstract
BACKGROUNDHomozygous deletion of 9p21 detected by fluorescence in situ hybridization (FISH) and loss of BRCA1-associated protein 1 (BAP1) expression detected by immunohistochemistry (IHC) are useful for the differentiation between malignant pleural mesothelioma (MPM) and reactive mesothelial hyperplasia. The authors previously described that IHC expression of the protein product of the methylthioadenosine phosphorylase (MTAP) gene, which is localized in the 9p21 chromosomal region, was correlated with the deletion status of 9p21 FISH in MPM tissues. In the current study, the authors investigated whether a combination of MTAP and BAP1 IHC could distinguish MPM from reactive mesothelial cells (RMC) in cell blocks obtained from pleural effusions. METHODSThe authors examined IHC expression of MTAP and BAP1 in cell blocks obtained from pleural effusions of 45 cases of MPM and 21 cases of reactive mesothelial hyperplasia. Furthermore, IHC expression of MTAP was compared with the deletion status of 9p21 FISH. RESULTSMTAP and BAP1 IHC differentiated MPM from RMC with 100% specificity for both and sensitivities of 42.2% and 60.0%, respectively. The combination of MTAP and BAP1 IHC yielded a sensitivity of 77.8%, which was higher than that of BAP1 IHC alone or 9p21 FISH alone (62.2%). Moreover, a high degree of concordance was observed between the results of MTAP IHC and 9p21 FISH in cell blocks. CONCLUSIONSA combination of MTAP and BAP1 IHC in cell blocks from pleural effusions appears to be a reliable and useful method for differentiating MPM cells from RMC and can be used in the routine diagnosis of MPM. Cancer Cytopathol 2018;126:54-63. (c) 2017 American Cancer Society. In cell blocks obtained from pleural effusions of malignant pleural mesothelioma, methylthioadenosine phosphorylase (MTAP) is a reliable immunohistochemistry (IHC) marker that can substitute for 9p21 fluorescence in situ hybridization (FISH). A combination of MTAP and BRCA1-associated protein 1 (BAP1) IHC is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia, with greater diagnostic sensitivity than that of BAP1 IHC alone or 9p21 FISH alone.Funding Information
- Ministry of the Environment
This publication has 56 references indexed in Scilit:
- IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial ProliferationsThe American Journal of Surgical Pathology, 2013
- Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesotheliomaCancer Science, 2012
- Germline BAP1 mutations predispose to malignant mesotheliomaNature Genetics, 2011
- Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion CytologySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesotheliomaJournal of Clinical Pathology, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of MesotheliomaCancer Research, 2009
- A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancerInvestigational New Drugs, 2008
- Population based epidemiology and prognosis of mesothelioma in Leeds, UKThorax, 2008
- Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian registerEuropean Journal of Cancer, 2007